A 52-year-old postmenopausal woman with newly diagnosed hormone receptor-positive (HR+), HER2-negative breast cancer presents for treatment planning. She has no prior history of thromboembolic disease or endometrial pathology. What is the drug of choice for first-line endocrine therapy in this patient?